
Horizon Therapeutics Public Limited Company – NASDAQ:HZNP
Horizon Therapeutics Public Limited Company stock price monthly change
Horizon Therapeutics Public Limited Company stock price quarterly change
Horizon Therapeutics Public Limited Company stock price yearly change
Horizon Therapeutics Public Limited Company key metrics
Market Cap | N/A |
Enterprise value | 25.08B |
P/E | 49.34 |
EV/Sales | 6.91 |
EV/EBITDA | 25.06 |
Price/Sales | 6.85 |
Price/Book | 4.90 |
PEG ratio | -12.99 |
EPS | 1.92 |
Revenue | 3.64B |
EBITDA | 957.02M |
Income | 438.00M |
Revenue Q/Q | 7.82% |
Revenue Y/Y | -4.42% |
Profit margin | 14.37% |
Oper. margin | 19.59% |
Gross margin | 74.64% |
EBIT margin | 19.59% |
EBITDA margin | 26.26% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHorizon Therapeutics Public Limited Company stock price history
Horizon Therapeutics Public Limited Company stock forecast
Horizon Therapeutics Public Limited Company financial statements
Sep 2022 | 925.35M | 135.83M | 14.68% |
---|---|---|---|
Dec 2022 | 942.02M | 120.40M | 12.78% |
Mar 2023 | 832.05M | 54.68M | 6.57% |
Jun 2023 | 944.95M | 127.07M | 13.45% |
2023-03-01 | 1.09 | 1.21 |
---|---|---|
2023-05-03 | 1.17 | 0.83 |
2023-08-08 | 1.12 | 1.2 |
2023-11-01 | 1.22 | 1.25 |
Sep 2022 | 9027862000 | 3.99B | 44.24% |
---|---|---|---|
Dec 2022 | 9114616000 | 4.04B | 44.35% |
Mar 2023 | 8993450000 | 3.89B | 43.34% |
Jun 2023 | 9298741000 | 3.98B | 42.89% |
Sep 2022 | 366.46M | -32.02M | -94.37M |
---|---|---|---|
Dec 2022 | 426.39M | -49.07M | -160.96M |
Mar 2023 | 86.32M | -41.75M | -88.12M |
Jun 2023 | 161.46M | -20.02M | 9.03M |
Horizon Therapeutics Public Limited Company alternative data
Aug 2023 | 2,145 |
---|---|
Sep 2023 | 2,190 |
Oct 2023 | 2,190 |
Nov 2023 | 2,190 |
Dec 2023 | 2,190 |
Jan 2024 | 2,190 |
Feb 2024 | 2,190 |
Mar 2024 | 2,190 |
Apr 2024 | 2,190 |
May 2024 | 2,190 |
Jun 2024 | 2,190 |
Jul 2024 | 2,190 |
Horizon Therapeutics Public Limited Company other data
Period | Buy | Sel |
---|---|---|
Feb 2022 | 0 | 101313 |
Mar 2022 | 0 | 174933 |
Apr 2022 | 0 | 477366 |
May 2022 | 0 | 100000 |
Jun 2022 | 0 | 25762 |
Jul 2022 | 0 | 10939 |
Aug 2022 | 745 | 0 |
Dec 2022 | 0 | 58521 |
Jan 2023 | 0 | 75200 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | MAHONY SUSAN director | Restricted Stock Units | 3,913 | N/A | N/A | ||
Option | DANIEL WILLIAM F director | Ordinary Shares | 3,913 | N/A | N/A | ||
Option | DANIEL WILLIAM F director | Restricted Stock Units | 3,913 | N/A | N/A | ||
Option | HIMAWAN JEFF director | Ordinary Shares | 3,913 | N/A | N/A | ||
Option | HIMAWAN JEFF director | Restricted Stock Units | 3,913 | N/A | N/A | ||
Option | GREY MICHAEL G director | Ordinary Shares | 3,913 | N/A | N/A | ||
Option | GREY MICHAEL G director | Restricted Stock Units | 3,913 | N/A | N/A | ||
Option | SHANNON JAMES SAMUEL director | Ordinary Shares | 3,913 | N/A | N/A | ||
Option | SHANNON JAMES SAMUEL director | Restricted Stock Units | 3,913 | N/A | N/A | ||
Option | MAHONY SUSAN director | Ordinary Shares | 3,913 | N/A | N/A |
Quarter | Transcript |
---|---|
Q3 2022 2 Nov 2022 | Q3 2022 Earnings Call Transcript |
Q2 2022 3 Aug 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 4 May 2022 | Q1 2022 Earnings Call Transcript |
Q4 2021 1 Mar 2022 | Q4 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Timothy P. Walbert (1967) Chairman, Pres & Chief Executive Officer | $5,480,000 |
Mr. Paul W. Hoelscher (1965) Executive Vice President & Chief Financial Officer | $1,880,000 |
Mr. Andy Pasternak (1971) Executive Vice President & Chief Strategy Officer | $1,790,000 |
Mr. Barry J. Moze (1954) Executive Vice President & Chief Admin. Officer | $1,710,000 |
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. (1955) Executive Vice President & Chief Medical Officer | $1,550,000 |
Improved Outlook For Horizon Therapeutics And Amgen
Viridian: Despite Drop, Advancement Towards Phase 3 Continues
Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half
Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'
Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price
Horizon Therapeutics: Attractive 5.4% Upside To Amgen Offer
Why Viridian Therapeutics Is One Of My 2023 Top Picks
Ranking The 10 Largest Biotechs By Pipeline
-
When is Horizon Therapeutics Public Limited Company's next earnings date?
Unfortunately, Horizon Therapeutics Public Limited Company's (HZNP) next earnings date is currently unknown.
-
Does Horizon Therapeutics Public Limited Company pay dividends?
No, Horizon Therapeutics Public Limited Company does not pay dividends.
-
What is Horizon Therapeutics Public Limited Company's stock symbol?
Horizon Therapeutics Public Limited Company is traded on the NASDAQ under the ticker symbol "HZNP".
-
What is Horizon Therapeutics Public Limited Company's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Horizon Therapeutics Public Limited Company?
Shares of Horizon Therapeutics Public Limited Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Horizon Therapeutics Public Limited Company's key executives?
Horizon Therapeutics Public Limited Company's management team includes the following people:
- Mr. Timothy P. Walbert Chairman, Pres & Chief Executive Officer(age: 58, pay: $5,480,000)
- Mr. Paul W. Hoelscher Executive Vice President & Chief Financial Officer(age: 60, pay: $1,880,000)
- Mr. Andy Pasternak Executive Vice President & Chief Strategy Officer(age: 54, pay: $1,790,000)
- Mr. Barry J. Moze Executive Vice President & Chief Admin. Officer(age: 71, pay: $1,710,000)
- Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. Executive Vice President & Chief Medical Officer(age: 70, pay: $1,550,000)
-
How many employees does Horizon Therapeutics Public Limited Company have?
As Jul 2024, Horizon Therapeutics Public Limited Company employs 2,190 workers.
-
When Horizon Therapeutics Public Limited Company went public?
Horizon Therapeutics Public Limited Company is publicly traded company for more then 14 years since IPO on 28 Jul 2011.
-
What is Horizon Therapeutics Public Limited Company's official website?
The official website for Horizon Therapeutics Public Limited Company is horizontherapeutics.com.
-
How can i contact Horizon Therapeutics Public Limited Company?
Horizon Therapeutics Public Limited Company can be reached via phone at +353 1 772 2100.
Horizon Therapeutics Public Limited Company company profile:

Horizon Therapeutics Public Limited Company
horizontherapeutics.comNASDAQ
2,190
Drug Manufacturers - General
Healthcare
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Dublin, 2
CIK: 0001492426
ISIN: IE00BQPVQZ61
CUSIP: G46188101